KINTOR
LIVE

Serial Number

90726883

Owner

Kintor Pharmaceutical Limited

Attorney

Alex Patel

Filing Date

May 21, 2021

Add to watchlist:

No watchlists yet
View on USPTO

KINTOR Trademark

Serial Number: 90726883 • Registration: 6785290

KINTOR is a trademark filed by Kintor Pharmaceutical Limited on May 21, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Kintor Pharmaceutical Limited (3 trademarks)

P.O. Box 2075, #31 The Strand
Grand Cayman , KY

Entity Type: 99

SUZHOU KINTOR PHARMACEUTICALS, INC. (6 trademarks)

NO.20, SONGBEI ROAD, SUZHOU INDUSTRIAL PARK
SUZHOU CITY, JIANGSU PROVINCE 215123 , CN

Entity Type: 99

Trademark Details

Filing Date

May 21, 2021

Registration Date

July 12, 2022

Published for Opposition

April 26, 2022

Goods & Services

Medicines for treatment of cancer; sachets for pharmaceutical purposes, medicines in the form of capsules, chemico-pharmaceutical preparations, drugs for medical purposes, chemical preparations for pharmaceutical purposes, biological preparations for medical purposes, chemical preparations for medical purposes, all of the foregoing for the treatment of cancer; anti-cancer pharmaceutical preparations; pharmaceutical preparations for the diagnosis and treatment of cancer; pharmaceutical products for the prevention, diagnosis, treatment and adjunctive therapy of cancer, cardiovascular disease, nervous system diseases, infectious diseases, respiratory diseases, endocrine and metabolic diseases, mental disorder, skin disease, diseases of the blood system, digestive system diseases, immune system diseases, diseases of genitourinary system, ocular diseases, otolaryngology and dentistry diseases, musculoskeletal and connective tissue diseases, nutritional diseases, diseases caused by external factors, namely, poisoning and injury; compounds for treating cancer; pharmaceuticals, medical and veterinary preparations for the prevention, diagnosis, treatment and adjunctive therapy of cancer, cardiovascular disease, nervous system diseases, infectious diseases, respiratory diseases, endocrine and metabolic diseases, mental disorder, skin disease, diseases of the blood system, digestive system diseases, immune system diseases, diseases of genitourinary system, ocular diseases, otolaryngology and dentistry diseases, musculoskeletal and connective tissue diseases, nutritional diseases, diseases caused by external factors, namely, poisoning and injury; sanitary preparations for medical purposes; dietetic food and substances, namely, dietetic foods, sugar substitutes, nutritional beverages, and dietary supplements for weight loss adapted for medical and veterinary use; food for babies; dietary supplements for humans and animals; plasters and materials, namely, gauze for medical dressings; materials for dental fillings and for sealing purposes; dental wax; disinfectants; preparations for destroying vermin; fungicides; herbicides; pharmaceutical preparations for the prevention, diagnosis, treatment and adjunctive therapy of coronaviruses, Covid-19, influenza viruses, influenza A, influenza B, SARS-CoV-1, SARSCoV-2, MERS-CoV, and rhinoviruses

Scientific and medical research services; pharmaceutical research services; research relating to pharmaceuticals; research and development of pharmaceutical products; biotechnology research; biochemistry and chemical research services; scientific research relating to biology and chemistry; scientific research in the field of pharmacy; scientific research into the development of new products; testing services for assessing the efficacy and safety of pharmaceuticals; preparation of reports relating to scientific research; analytical medical and scientific laboratory services; medical and scientific laboratory research and analysis; development of products; development of pharmaceutical preparations for the diagnosis and treatment of cancer; advisory services relating to scientific research; scientific and technological services in the field of pharmaceuticals and research and design relating thereto, namely, consulting and advisory services, CRO (Contract Research Organization) and CDMO (Contract Development and Manufacturing Organization) services; industrial analysis and research services in the field of pharmaceuticals; design and development of computer hardware and software; information, advisory and consultancy services relating to all the aforesaid services

Filing History

AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
May 7, 2025 ASGN
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Apr 23, 2025 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 23, 2025 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Apr 23, 2025 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 23, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 23, 2025 REAP
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jul 12, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
Jul 12, 2022 R.PR
POST PUBLICATION AMENDMENT - ENTERED
May 4, 2022 CHPB
WITHDRAWN FROM ISSUE - PETITIONS OFFICE REQUEST
Apr 26, 2022 ISPO
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 26, 2022 NPUB
PUBLISHED FOR OPPOSITION
Apr 26, 2022 PUBO
ASSIGNED TO PETITION STAFF
Apr 19, 2022 APET
TEAS POST PUBLICATION AMENDMENT RECEIVED
Apr 7, 2022 EPPA
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 6, 2022 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Mar 23, 2022 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 22, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 15, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 15, 2022 CRFA
ASSIGNED TO LIE
Mar 14, 2022 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 12, 2022 TROA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Feb 20, 2022 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 20, 2022 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Feb 20, 2022 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 20, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 20, 2022 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Feb 20, 2022 COAR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 28, 2021 GNRN
NON-FINAL ACTION E-MAILED
Dec 28, 2021 GNRT
NON-FINAL ACTION WRITTEN
Dec 28, 2021 CNRT
ASSIGNED TO EXAMINER
Dec 22, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 18, 2021 NWOS
NEW APPLICATION ENTERED
May 25, 2021 NWAP